Highlights
- Spleen volume ≥500 mL or length ≥140 mm serves as a critical threshold, where the 5-year absolute risk of hematologic cancer reaches up to 46% in elderly populations.
- Incidentally detected splenomegaly is a potent predictor not only of hematologic malignancies but also of cirrhosis and primary liver cancer.
- Specific quantitative cutoffs (length 130-139 mm; volume 400-499 mL) define a ‘moderate risk’ zone requiring clinical vigilance.
- The integration of age, sex, and splenic metrics is essential for personalized risk assessment and determining the necessity of invasive workups like bone marrow biopsy.
Background
Splenomegaly is a frequent incidental finding in modern clinical practice due to the ubiquitous use of high-resolution computed tomography (CT) and magnetic resonance imaging (MRI). While traditionally associated with portal hypertension or lymphoproliferative disorders, the clinical significance of an incidentally discovered enlarged spleen in an asymptomatic patient remains a diagnostic challenge. Until recently, there was a lack of robust, population-based evidence defining the exact spleen dimensions that should trigger a comprehensive hematologic or hepatologic evaluation. Clinicians often grapple with whether to pursue expectant management or invasive diagnostics, a dilemma compounded by the varying definitions of ‘normal’ splenic size across different demographic groups. Recent large-scale prospective cohort studies have now provided a much-needed evidence base to quantify these risks.
Key Content
Quantitative Thresholds for Malignancy and Liver Disease
A landmark prospective cohort study by Juhl et al. (2026), involving over 47,000 individuals from Denmark and the UK, has clarified the relationship between splenic dimensions and long-term outcomes. The study utilized both spleen length and volume to categorize risk.
Relative risks for hematologic cancer were found to increase dramatically at the extremes of splenic size. For individuals with a spleen volume above the 99th percentile (≥433 mL in the Danish cohort; ≥386 mL in the UK cohort), the hazard ratio (HR) for hematologic cancer was approximately 11.0 to 11.8 compared to those in the interquartile range. Spleen length also served as a viable marker; lengths exceeding 134 mm (99th percentile) were associated with a five-fold increase in the relative risk of hematologic malignancies.
Absolute Risk Trajectories by Age and Sex
The most clinically impactful finding of recent research is the calculation of absolute 5-year risks, which vary significantly by age and sex:
- Moderate Risk (Length 130-139 mm or Volume 400-499 mL): In this range, risks are elevated but may not immediately warrant invasive procedures unless other clinical symptoms or cytopenias are present.
- High Risk (Length ≥140 mm or Volume ≥500 mL): In men aged 70 or older with a spleen volume ≥500 mL, the 5-year absolute risk of developing a hematologic cancer was as high as 46% (Denmark) and 21% (UK). For women in the same age bracket, the risk reached 27%.
The Spleen-Liver Axis: Cirrhosis and Hepatocellular Carcinoma
Splenomegaly is not solely a harbinger of hematologic disease. The UK-based cohort data demonstrated that a spleen volume ≥400 mL is associated with a substantially increased 5-year risk of cirrhosis and liver cancer. For individuals over 70 with a spleen volume ≥500 mL, the risk of cirrhosis was approximately 10.8% for men and 9.3% for women. Even at slightly lower volumes (≥400 mL), the 5-year risk of liver cancer was significantly elevated (3.2% in men), suggesting that splenomegaly may be an early indicator of occult chronic liver disease or Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).
Underlying Pathophysiological Mechanisms
To understand why splenomegaly predicts these outcomes, one must look at the broader landscape of splenic and hepatic iron and metabolic regulation. Research into SLC40A1-related hemochromatosis (ferroportin disease) highlights how splenic iron overload can occur alongside hepatic overload, contributing to systemic fibrosis risk. Phenotypic variability in these rare iron disorders often presents with splenic involvement, reinforcing the need to consider metabolic and genetic iron overload when splenomegaly is detected. Furthermore, the progression of MASLD (formerly NAFLD) to MASH-related fibrosis—driven by mechanisms such as succinate GPR91 activation of stellate cells—often manifests as portal hypertension and subsequent splenomegaly long before overt cirrhosis is diagnosed.
Expert Commentary
The data from Juhl et al. represent a paradigm shift in the management of incidental splenomegaly. For years, a length of 12 cm was loosely considered the upper limit of normal, but these new findings suggest that we must adopt a more nuanced, ‘risk-based’ approach rather than a binary ‘normal vs. abnormal’ classification.
One controversy remains: the discrepancy between volume and length. While volume is a more precise measure of splenic mass, length is more easily obtained in routine clinical reports. The evidence suggests that volume is a more potent predictor of malignancy, likely because it captures three-dimensional expansion that a single longitudinal measurement might miss.
Clinicians should also be aware of the ‘prognostic middle ground.’ As highlighted in recent hepatology literature, even ‘trace’ or ‘mild’ findings—such as mild ascites or moderate splenomegaly—are not trivial and often represent the tipping point toward decompensation in chronic liver disease. The clinical workup for a patient with a spleen ≥140 mm should arguably include a peripheral blood smear, flow cytometry, and a comprehensive liver stiffness assessment (FibroScan) or specialized imaging, even in the absence of symptoms.
Conclusion
Incidentally detected splenomegaly is a high-value clinical signal. A spleen length of 140 mm or a volume of 500 mL should be viewed as a definitive threshold for comprehensive clinical investigation, given the high absolute 5-year risks of hematologic cancer and cirrhosis. Future research should focus on whether early intervention in these high-risk asymptomatic individuals improves survival outcomes and whether automated AI-based splenic volume measurement can be integrated into radiology workflows to improve early detection of occult disease.
References
- Juhl AR, et al. Incidentally Detected Splenomegaly and Risk of Hematologic Cancer and Liver Disease. JAMA oncology. 2026;12(3):275-284. PMID: 41538177.
- Schaefer B, et al. Characterization of ferroportin disease and SLC40A1-related hemochromatosis – Results from the EASL non-HFE registry. J Hepatol. 2026;84(4):728-737. PMID: 41855270.
- Vilar-Gomez E, et al. When “trace” is not trivial: Mild ascites as the missing prognostic middle ground in cirrhosis. Hepatology. 2026;83(4):695-696. PMID: 41849184.
- Succinate GPR91 activation of stellate cells in MASH. Hepatology. 2026;83(4):699-700. PMID: 41849186.
- MASLD and breast cancer risk: The role of hepatocyte-derived exosomes. J Hepatol. 2026;84(4):837-839. PMID: 41735155.